ISRCTN94245451进行中（未招募）Unknown
A single-centre, randomised, parallel-group, double-blinded placebo-controlled study to compare the impact of non-invasive pre-operative electrical stimulation versus placebo on nerve regeneration following decompression surgery for carpal tunnel syndrome
适应症
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Participant is willing and able to give informed consent for participation in the study.
- •2. Male or female, aged 18 years old and over
- •3. Diagnosed with carpal tunnel syndrome based on clinical examination by a hand surgeon
- •4. The patient has already determined they wish to proceed with carpal tunnel decompression surgery
排除标准
- •The participant may not enter the study if ANY of the following apply:
- •1. Previous major hand, wrist surgery or forearm on the side affected by CTS, defined as previous carpal tunnel release, previous nerve repair, implantation of metalwork
- •2. Post-traumatic CTS
- •3. Previous electrical stimulation treatment of any kind, including implanted electrical stimulation devices such as cardiac pacemakers
- •4. Current pregnancy or CTS which developed during a previous pregnancy
- •5. Any peripheral neuropathy other than CTS
- •6. Another medical condition affecting the upper limb and neck (e.g., rheumatoid arthritis, cervical radiculopathy)
- •7. Diabetes mellitus
- •8. Hypothyroidism
- •9. Severe anxiety or depression
- •10. Conditions affecting pain perception (e.g. fibromyalgia)
- •11. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the Study, or may influence the result of the study, or the patient’s ability to participate in the study.
- •12. Evidence of motor conduction block across the carpal tunnel on neurophysiological testing
- •13. Patients with insufficient command of English to obtain consent from or to complete the study questionnaires.
- •14. Patients with insufficient mental capacity to obtain consent from or to complete the study questionnaires
- •15. Patients who in the opinion of the consultant in charge of their care, or the chief investigator, are unsuitable for participation in the study.
研究者
相似试验
进行中（未招募）
不适用
A clinical study to assess the efficacy and safety of Oscillococcinum® in the treatment of symptoms of influenza-like illness (ILI), when compared with placebo (a sugar pill without oscillococcinum). The study treatment is given in a randomised, parallel group, double-blind (neither patient or doctor aware of which treatment they have) manner, in several study centres.Systemic and respiratory symptoms of Influenza-like-illness (ILI)MedDRA version: 14.1Level: LLTClassification code 10016797Term: Flu-like symptomsSystem Organ Class: 100000004867EUCTR2013-001869-16-DEBoiron Laboratoires
进行中（未招募）
不适用
A clinical study to assess the efficacy and safety of Octenidine lozenges in the treatment of acute sore throat. Octenedine Lozenges will be compared with an active comparator and against placebo in patients at multiple sites, in a double blind ( patient and doctor) randomised manner.Acute pharyngitisEUCTR2012-002876-15-DECassella-med GmbH & Co KG
已完成
不适用
A multicentre, parallel group, randomised, double blind study to investigate the efficacy of fluticasone 100 mcg metered dose inhaler (MDI) twice a day (bd) versus placebo MDI bd both via Babyhaler® spacer in 1 to 5 year old children with asthma or asthma-like symptoms during a 6 month study periodAsthmaRecurrent respiratory symptoms in childrenRespiratoryISRCTN04517206GlaxoSmithKline (The Netherlands)96
进行中（未招募）
1 期
Reperfusion thrombolytic therapy for ischemic stroke in patients on the non-vitamin K antagonist oral anticoagulants.EUCTR2020-004898-41-PLMEDICAL UNIVERSITY OF GDANSK300
进行中（未招募）
1 期
A randomized, multi-center, parallel group, double-blind, placebo and formetrol controlled 14 day dose ranging trial of 4 doses of indacaterol delivered via Twisthaler®, in adult and adolescent patients with persistent asthmaEUCTR2007-003191-19-PLovartis Pharma Services AG488